Filing Details
- Accession Number:
- 0001725160-21-000206
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-10-27 20:13:13
- Reporting Period:
- 2021-10-25
- Accepted Time:
- 2021-10-27 20:13:13
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1725160 | Zentalis Pharmaceuticals Inc. | ZNTL | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1819302 | Alexis Pinto | C/O Zentalis Pharmaceuticals, Inc. 530 Seventh Avenue, Suite 2201 New York NY 10018 | Chief Legal Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-10-25 | 30,000 | $34.40 | 36,526 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-10-25 | 1,800 | $76.10 | 34,726 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-25 | 8,098 | $77.27 | 26,628 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-25 | 19,802 | $78.05 | 6,826 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2021-10-25 | 300 | $78.85 | 6,526 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2021-10-25 | 30,000 | $0.00 | 30,000 | $34.40 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 245,000 | 2030-08-30 | No | 4 | M | Direct |
Footnotes
- The stock option exercise and sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
- Includes 276 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on September 30, 2021.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $75.57 to $76.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $76.59 to $77.58. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $77.59 to $78.44. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The options vest and become exercisable as to 25% of the total number of shares underlying the option on August 31, 2021 and as to the remaining 75% in 36 substantially equal monthly installments thereafter.
Billionaire Hedge Funds
